AN ECONOMIC SYSTEMATIC LITERATURE REVIEW FOR UNTREATED ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK+) NON-SMALL-CELL LUNG CANCER (NSCLC)
Author(s)
Hibbs R1, Prowse A2, Strickson A2, Cooper C3
1Tolley Health Economics, Buxton, DBY, UK, 2Tolley Health Economics, Buxton, UK, 3University College London, London, UK
Presentation Documents
OBJECTIVES : To conduct a systematic literature review (SLR) of health economic evidence (cost-effectiveness models, cost/resource use, utility inputs) to inform an economic model of anaplastic lymphoma kinase (ALK) inhibitors for first-line (1L) treatment of ALK+ non-small cell lung cancer (NSCLC). METHODS Two searches were conducted in May 2018 for cost-effectiveness and cost and resource use components, and for the health-related quality of life (HRQoL) evidence. Systematic searches of bibliographic databases and conference websites were conducted alongside hand-searching health technology assessment websites (HTA). Abstract and full-text screening for inclusion was conducted by two independent reviewers. Study quality was assessed using a range of appraisal checklists: Methods for the Development of NICE Public Health Guidance and Philips et al. (2004) for cost-effectiveness and cost and resource use publications; Picot et al. (2015) for HRQoL publications. RESULTS : A total of 1,708 records were identified from the bibliographic and conference searches (n=1,696), HTA website searches (n=11) and hand-searching (n=1). After full-text screening (n=315), 42 publications were included for data extraction across all three SLR components, of which some were relevant to more than one component. Eight publications provided evidence directly relating to first-line ALK+ NSCLC economic evidence, 29 contained relevant cost/resource use data, and 21 contained HRQoL utility data. Nine of the 18 economic articles detailed three-state partitioned-survival models whilst one presented a four-state model separating progression by the presence of central nervous system metastases. CONCLUSIONS : The SLR identified limited articles from the bibliographic and conference searches in the 1L population but web searches identified recent economic evaluations in the form of cost-utility analyses submitted to HTA bodies such as NICE. The SLR confirmed that a three-state partitioned-survival model is the most widely used but a four-state model had recently been submitted for HTA. Updates to the SLR are currently ongoing (searches: June 2019).
Conference/Value in Health Info
2019-11, ISPOR Europe 2019, Copenhagen, Denmark
Code
PCN155
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis, Work & Home Productivity - Indirect Costs
Disease
Oncology, Respiratory-Related Disorders